Tesamorelin (5mg) / Ipamorelin (1mg) – About This Product
The tesamorelin ipamorelin peptide is a combined research formulation composed of two synthetic peptides studied for their roles in growth hormone (GH) regulation. This product contains Tesamorelin (5 mg), a stabilized 44–amino acid analog of human growth hormone–releasing hormone (GHRH), and Ipamorelin (1 mg), a selective pentapeptide GH secretagogue. The blend is supplied as a lyophilized powder in a sealed vial for controlled laboratory research use.
- Tesamorelinb: Incorporates an N-terminal trans-3-hexenoic acid modification, which improves resistance to enzymatic degradation and supports prolonged biological activity compared with native GHRH.
- Ipamorelin: Designed to selectively stimulate GH release with minimal interaction with other pituitary hormones and is recognized as the first selective GH secretagogue. Unlike earlier GH secretagogues, it does not significantly elevate cortisol, prolactin, acetylcholine, or aldosterone in published research.
Together, this formulation is investigated in experimental settings focused on endocrine signaling, metabolic regulation, and body-composition research. Research-grade materials are commonly manufactured with high analytical purity (≥98%) to support reproducibility in laboratory studies.
Biochemical Characteristics
Tesamorelin (5 mg component)
- Peptide type: Stabilized GHRH analog
- Amino acid sequence: 44-amino acid peptide with N-terminal trans-3-hexenoic acid modification
- Molecular weight: 5,195.908 g/mol
- Molecular formula: C₂₂₃H₃₇₀N₇₂O₆₉S
- CAS number: 901758-09-6
- PubChem CID: 44147413
Ipamorelin (1 mg component)
- Amino acid sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Peptide type: Selective GH secretagogue
- Molecular weight: 711.85 Da (711.868 g/mol)
- Molecular formula: C₃₈H₄₉N₉O₅
- CAS number: 170851-70-4
- PubChem CID: 9831659
Tesamorelin (5mg) / Ipamorelin (1mg) Key Features and Benefits
- Dual-peptide formulation: Tesamorelin (5 mg) + Ipamorelin (1 mg) in one research vial
- Complementary GH stimulation: GHRH-mediated signaling plus ghrelin-pathway activation
- Tesamorelin component: Supports physiologic GH pulsatility via GHRH receptor engagement
- Ipamorelin component: Highly selective GH secretagogue with minimal off-target hormone release
- Lyophilized format: Enables precise reconstitution and flexible experimental design
- High-purity research grade: Suitable for in vitro and in vivo investigations
- For research use only: Not approved for human or veterinary administration
Tesamorelin (5mg) / Ipamorelin (1mg) Mechanism & Research Applications
This peptide combination is investigated for its ability to stimulate endogenous GH release through two distinct but complementary mechanisms.
- Tesamorelin: Activates the GHRH receptor, promoting cAMP-mediated signaling and physiologic GH secretion.
- Ipamorelin: Stimulates GH release via ghrelin-associated pathways, enhancing pituitary responsiveness without broad endocrine activation.
By combining tesamorelin and ipamorelin, researchers explore whether synergistic effects may occur, as each peptide engages the GH axis through a different mechanism. Together, they are studied for their potential to stimulate the pituitary to secrete endogenous GH at more physiologic levels than single-agent models.
Research applications include:
- GH axis modulation and endocrine feedback regulation
- Metabolic research involving lipid handling and energy balance
- Visceral adipose tissue (VAT) dynamics in experimental models
- Lean tissue and muscle maintenance research
- Sleep and recovery investigations, where GH release is contributory
- Exploratory IGF-1 signaling studies related to cellular repair and aging processes
All applications described are investigational and conducted under regulated laboratory or research protocols.
Tesamorelin (5mg) / Ipamorelin (1mg) Dosing & Observed Effects in Research
Published research has most extensively evaluated Tesamorelin as a standalone agent at 2 mg once daily in human clinical studies.
Ipamorelin has been examined in experimental settings at 100–300 μg per administration, typically delivered 2–3 times daily via subcutaneous injection in human research protocols. Animal studies have evaluated doses ranging from 100 to 1000 μg/kg.
Reported observations include:
- Increased GH and IGF-1 levels in responder populations, with IGF-1 increases of approximately 181 μg/L (representing ~100–120% above baseline) documented in tesamorelin studies
- Tesamorelin as a standalone agent demonstrating 15–20% reductions in visceral adipose tissue in responder populations over 26-week protocols
- Preservation of lean muscle mass in catabolic and aging models
- Improved sleep parameters, including enhanced slow-wave sleep in some investigations
- Variable glucose responses, requiring stratification by responder status
Published tesamorelin research protocols have primarily evaluated treatment durations of 26 weeks to 12 months, whereas ipamorelin investigations have ranged from 4 to 12 weeks. Combination protocols remain investigational, with limited published data on duration. Effects on body composition are generally not maintained after discontinuation, with visceral fat reaccumulation reported once exposure ceases.
Tesamorelin (5mg) / Ipamorelin (1mg) Storage, Safety & References
The tesamorelin ipamorelin peptide blend should be stored as a lyophilized powder at –20 °C or colder. Short-term storage at 2–8 °C is acceptable during handling. Protect vials from light, heat, and moisture, and keep sealed until reconstitution.
After reconstitution with bacteriostatic water or an appropriate sterile diluent, store solutions at 2–8 °C and use within timeframes defined by laboratory protocols. Avoid repeated freeze–thaw cycles.
For research use only. Not for human consumption. Not for clinical, diagnostic, therapeutic, or veterinary use.
All handling, storage, and disposal must follow institutional biosafety and chemical hygiene guidelines. Laboratories that buy tesamorelin ipamorelin peptide or order tesamorelin ipamorelin peptide are responsible for regulatory compliance.
References
https://pubmed.ncbi.nlm.nih.gov/9849822
https://pubmed.ncbi.nlm.nih.gov/20943777
https://pubmed.ncbi.nlm.nih.gov/20554713
https://pubmed.ncbi.nlm.nih.gov/22495074
https://pubmed.ncbi.nlm.nih.gov/10496658
https://pubmed.ncbi.nlm.nih.gov/10604470
Compliance Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use.